Apremilast in the treatment of psoriatic arthritis: a perspective review

28Citations
Citations of this article
68Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4). Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis. Established therapeutic options have variable effectiveness across the different domains of psoriatic disease. Whilst biologic therapies have proven to be of significant benefit to many patients, not all patients respond, and others are not eligible or do not tolerate biologic therapy. We review the mechanism of action, pharmacokinetics and clinical trial data with regards to both efficacy and safety for apremilast and consider where this new treatment may be positioned in the treatment of PsA.

Cite

CITATION STYLE

APA

Reed, M., & Crosbie, D. (2017, February 1). Apremilast in the treatment of psoriatic arthritis: a perspective review. Therapeutic Advances in Musculoskeletal Disease. SAGE Publications Ltd. https://doi.org/10.1177/1759720X16673786

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free